Severe asthma is also a weakening condition and a clinician obstacle. New treatments were launched and asthma management was significantly improved, with further research or clinical trials. That includes anti-IL5/IL5R, anti-IL4/IL4R, anti-IL13, anti-thymic stromal lymphopoietin (TSLP) and more, and finally, a tailored solution to extreme asthma is being followed. However, a substantial group of serious asthma patients, in particular those with T2-low asthma, are now unable to discover new scientifically accessible biomarkers and specific therapies.

This study presents briefly the phénotypes and endoscopes of serious asthma, asthma omics technology and existing and potential therapies for both T2-high and T2-low asthma. The efficacy and safety of anti-IL5 treatments, dupilumab and tezepelumab clinical trials, as well as the most important biological molecules used in the T2-low asthma studies are presented. The treatment of T2 high asthma has changed with new anti-IL 5 inhibitors, resulting in better regulation of diseases, QoL and lung functions, and much less exacerbations. However, new therapies are still needed for T2-low asthma.